SCUBE3 and GT20029 could be the closet thing to a cure: Hair Follicle Regeneration and Protection Against DHT
    8/15/2023

    From the encyclopedia
    SCUBE3 →

    Signalling protein made in the hair follicle

    GT20029 →

    Experimental topical drug designed to break down androgen receptors

    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    At a glance
    In this hair loss treatment regimen post, the primary subjects mentioned are
    💧 SCUBE3 (topical)
    💧 GT20029 (topical)
    💊 Finasteride (oral)
    💊 Dutasteride (oral)
    the tone is 😐 neutral.

    Other terms

    SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community He used Dutasteride for 20 YEARS: TL;DR Slight gains and largely stable for 20 years.

       25 upvotes 2 years ago
      John has experienced slight hair gains and stability over 20 years using Dutasteride, which is more effective than Finasteride in reducing scalp DHT and maintaining hair. Dutasteride at 0.5mg daily has a similar side effect profile to Finasteride, but at higher doses, it may increase the risk of sexual side effects.

      community GT20029 and PP405 the new fin and min that we been waiting for ?

       36 upvotes 1 year ago
      PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community I hope ET-02 or PP405 will be released in the next 4-5 years

       18 upvotes 1 year ago
      PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

    Related Research

    6 / 6 results